-
受环境污染、人口老龄化、吸烟人数上升等众多因素的影响,我国肺癌发病率及死亡率均呈逐年上升趋势,我国大部分地区肺癌已成为发病率最高的恶性肿瘤。对于早、中期肺癌,手术根治是控制淋巴转移以及肺动脉结构进行性病变的主要方法,能保留并保护正常的肺组织,延长病人生存时间[1]。但我们在临床观察中发现,手术对肺组织有损伤,术后肺功能会出现明显下降,并出现严重的炎症反应与应激反应等。因此,降低肺癌根治术肺损伤,术后及时改善肺功能及炎性反应对肺癌根治术病人短期预后的提升具有十分重要的意义[2]。近年来研究发现氨溴索具有较强的抗炎、抗氧化以及肺保护作用,在部分胸外科手术后咳嗽、呼吸困难中具有一定的运用效果,但临床报道以小剂量居多[3]。针对肺癌根治术造成的肺损伤及炎性、氧化应激反应,我院在围手术期运用大剂量氨溴索静脉滴注,旨在改善术后早期肺功能及炎症反应。现作报道。
-
2组术后5 d肺功能指标均明显低于术前,咳痰难易程度评分明显高于术前(P < 0.01)。观察组术后5 d PEF25明显高于对照组,咳痰难易程度评分低于对照组(P < 0.01和P < 0.05)(见表 1)。
分组 n PEF25/(L/s) FEV1/L FVC/L 咳痰难易程度评分/分 术前 观察组 45 3.34±0.58 2.12±0.34 2.65±0.54 1.21±0.23 对照组 45 3.38±0.52 2.15±0.31 2.64±0.61 1.19±0.26 t — 0.34 0.44 0.08 0.39 P — >0.05 >0.05 >0.05 >0.05 术后5 d 观察组 45 2.97±0.51** 1.92±0.45** 2.29±0.50** 1.45±0.30** 对照组 45 2.61±0.48** 1.77±0.28** 2.10±0.62** 1.60±0.32** t — 3.45 1.90 1.60 2.29 P — < 0.01 >0.05 >0.05 < 0.05 组内配对t检验:**P < 0.01 表 1 2组手术前后肺部功能比较($\overline x \pm s$)
-
2组术后1 d血清IL-6、IL-8、CRP水平较术前明显升高,观察组术后5 d IL-6、IL-8、CRP水平均明显高于术前和低于术后1 d,观察组术后1 d、5 d组IL-6、IL-8、CRP水平均明显低于对照组(P < 0.01)(见表 2)。
分组 术前 术后1 d 术后5 d F P MS组内 IL-6/ (ng/L) 观察组 11.65±1.56 19.23±3.18** 12.32±1.24## 168.79 < 0.01 4.695 对照组 11.47±1.52 26.23±3.72** 16.54±2.41**## 957.16 < 0.01 7.319 t 0.55 9.60 10.44 — — — P >0.05 < 0.01 < 0.01 — — — IL-8/(ng/L) 观察组 4.23±0.67 12.23±1.12** 5.12±0.45**## 1361.76 < 0.01 0.635 对照组 4.20±0.51 19.34±1.87** 8.01±0.78**## 1917.89 < 0.01 1.455 t 0.24 21.88 21.53 — — — P >0.05 < 0.01 < 0.01 — — — CRP/(mg/L) 观察组 4.63±0.89 18.23±3.45** 6.45±1.00**## 537.32 < 0.01 4.565 对照组 4.64±0.87 24.34±4.11** 10.34±2.12**## 626.51 < 0.01 7.381 t 0.05 7.64 11.02 — — — P >0.05 < 0.01 < 0.01 — — — q检验:与术前比较**P < 0.01;与术后1 d组比较##P < 0.01 表 2 2组血清炎性因子水平比较($\overline x \pm s$)
-
观察组住院时间、抗菌药物使用时间均明显低于对照组(P < 0.01)(见表 3)。
分组 n 住院时间/d 抗菌药物使用时间/d 观察组 45 9.12±2.01 4.32±1.56 对照组 45 12.07±2.98 6.01±1.69 t — 5.51 4.93 P — < 0.01 < 0.01 表 3 2组住院指标比较($\overline x \pm s$)
-
2组病人并发症差异无统计学意义(P>0.05)(见表 4)。术后胸片显示,病人均出血纵隔向术侧移位,膈肌升高等情况;对照组3例,观察组1例病人出现炎性病灶,1例表现为局限性脓胸。
分组 n 肺部感染 肺不张 脓胸 心律失常 χ2 P 观察组 45 1 0 0 1 2.24 >0.05 对照组 45 3 2 1 2 合计 90 4 2 1 3 表 4 2组并发症比较
大剂量盐酸氨溴索注射液对肺癌病人术后肺功能恢复的效果
Effect of high-dose ambroxol hydrochloride injection on postoperative lung function recovery in lung cancer patients
-
摘要:
目的探讨大剂量氨溴索注射液对肺癌病人术后肺功能恢复的效果。 方法纳入90例非小细胞肺癌病人,随机分为对照组与观察组,均采用胸腔镜根治手术,对照组手术前1 d与术后5 d给予常规剂量(60 mg/d)氨溴索静滴治疗,观察组采用大剂量(500 mg/d)氨溴索静滴治疗。比较2组病人住院相关指标、手术前后肺功能及血清炎性因子水平变化以及并发症发生情况。 结果2组术后5 d肺功能指标均明显低于术前,咳痰难易程度评分明显高于术前(P < 0.01)。观察组术后5 d PEF25明显高于对照组,咳痰难易程度评分低于对照组(P < 0.01和P < .05)。2组术后1 d血清IL-6、IL-8、CRP水平较术前明显升高,观察组术后5 d IL-6、IL-8、CRP水平均明显高于术前和低于术后1 d,观察组术后1 d、5 d组IL-6、IL-8、CRP水平均明显低于对照组(P < 0.01)。观察组住院时间、抗菌药物使用时间均明显低于对照组(P < 0.01)。2组并发症发生率差异无统计学意义(P>0.05)。 结论围手术期大剂量氨溴索能降低肺癌根治术病人肺损伤,促进肺功能的恢复,改善术后炎症反应,降低抗菌药物使用时间。 Abstract:ObjectiveTo explore the therapeutic effects of high-dose ambroxol hydrochloride injection on postoperative lung function recovery in patients with lung cancer. MethodsNinety patients with non-small-cell lung cancer(NSCLC) were randomly divided into the control group and observation group according to the digital table method.All patients were treated with thoracoscopic radical surgery.Before 1 day and after 5 days of operation, the control group and observation group were intravenously treated with the conventional dose of ambroxol(60 mg/d) and high-dose ambroxol(500 mg/d), respectively.The hospital-related indicators, lung function and serum levels of inflammatory factors before and after surgery, and complications were compared between two groups. ResultsThe postoperative pulmonary function indexes and score of expectoration degree of two groups after operation were significantly lower and higher than those before operation, respectively(P < 0.01).The PEF25 level and score of expectoration degree in observation group after 5 days of operation were significantly higher and lower than those in control group(P < 0.01 and P < 0.05).The serum levels of IL-6, IL-8 and CRP in two groups after 1 day of operation significantly increased compared with before operation, the serum levels of IL-6, IL-8 and CRP in observation group after 5 days of operation were significantly higher and lower than those before operation and after 1 day of operation, respectively, and the serum levels of IL-6, IL-8 and CRP in observation group after 1 day and 5 days of operation were significantly lower than those in control group(P < 0.01).The hospitalization time and antibacterial use time in observation group were significantly lower than those in control group(P < 0.01).There was no statistical significance in incidence rate of complications between two groups(P < 0.05). ConclusionsThe perioperative application of high-dose ambroxol can reduce lung injury, promote recovery of lung function, improve postoperative inflammatory response, and reduce antibacterial use time in patients with radical lung cancer. -
Key words:
- ambroxol /
- high-dose /
- radical lung cancer /
- lung resection of function /
- inflammatory factor
-
表 1 2组手术前后肺部功能比较(
)$\overline x \pm s$ 分组 n PEF25/(L/s) FEV1/L FVC/L 咳痰难易程度评分/分 术前 观察组 45 3.34±0.58 2.12±0.34 2.65±0.54 1.21±0.23 对照组 45 3.38±0.52 2.15±0.31 2.64±0.61 1.19±0.26 t — 0.34 0.44 0.08 0.39 P — >0.05 >0.05 >0.05 >0.05 术后5 d 观察组 45 2.97±0.51** 1.92±0.45** 2.29±0.50** 1.45±0.30** 对照组 45 2.61±0.48** 1.77±0.28** 2.10±0.62** 1.60±0.32** t — 3.45 1.90 1.60 2.29 P — < 0.01 >0.05 >0.05 < 0.05 组内配对t检验:**P < 0.01 表 2 2组血清炎性因子水平比较(
)$\overline x \pm s$ 分组 术前 术后1 d 术后5 d F P MS组内 IL-6/ (ng/L) 观察组 11.65±1.56 19.23±3.18** 12.32±1.24## 168.79 < 0.01 4.695 对照组 11.47±1.52 26.23±3.72** 16.54±2.41**## 957.16 < 0.01 7.319 t 0.55 9.60 10.44 — — — P >0.05 < 0.01 < 0.01 — — — IL-8/(ng/L) 观察组 4.23±0.67 12.23±1.12** 5.12±0.45**## 1361.76 < 0.01 0.635 对照组 4.20±0.51 19.34±1.87** 8.01±0.78**## 1917.89 < 0.01 1.455 t 0.24 21.88 21.53 — — — P >0.05 < 0.01 < 0.01 — — — CRP/(mg/L) 观察组 4.63±0.89 18.23±3.45** 6.45±1.00**## 537.32 < 0.01 4.565 对照组 4.64±0.87 24.34±4.11** 10.34±2.12**## 626.51 < 0.01 7.381 t 0.05 7.64 11.02 — — — P >0.05 < 0.01 < 0.01 — — — q检验:与术前比较**P < 0.01;与术后1 d组比较##P < 0.01 表 3 2组住院指标比较(
)$\overline x \pm s$ 分组 n 住院时间/d 抗菌药物使用时间/d 观察组 45 9.12±2.01 4.32±1.56 对照组 45 12.07±2.98 6.01±1.69 t — 5.51 4.93 P — < 0.01 < 0.01 表 4 2组并发症比较
分组 n 肺部感染 肺不张 脓胸 心律失常 χ2 P 观察组 45 1 0 0 1 2.24 >0.05 对照组 45 3 2 1 2 合计 90 4 2 1 3 -
[1] 焕松, 牟巨伟.非小细胞肺癌手术入路及切除方式研究进展[J].中国肺癌杂志, 2018, 21(9):692. [2] 冯海明, 赵晔, 马建兴, 等.不同手术方式对早期非小细胞肺癌患者术后肺功能影响的Meta分析[J].中国循证医学杂志, 2017, 17(8):87. [3] MARTÍNEZ-MARTÍNEZ LA, PÉREZ LF, BECERRIL-MENDOZA LT, et al.Ambroxol for fibromyalgia:one group pretest-posttest open-label pilot study[J].Lin Rheumatol, 2017, 36(8):1. [4] ETTINGER DS, WOOD DE, AISNER DL, et al.Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw, 2017, 15(4):504. doi: 10.6004/jnccn.2017.0050 [5] 宋振祥, 胡晓冬, 林韬, 等.单孔胸腔镜手术治疗肺癌的研究现状及进展[J].临床肺科杂志, 2017, 22(3):557. doi: 10.3969/j.issn.1009-6663.2017.03.048 [6] 胡一淼, 葛阳, 顾江魁, 等.单操作孔胸腔镜肺叶切除术治疗早期肺癌的临床分析[J].临床肺科杂志, 2017, 22(6):992. doi: 10.3969/j.issn.1009-6663.2017.06.006 [7] 尧云, 李学平, 许培阳.右美托咪啶对肺癌根治术患者围术期炎性反应及肺功能的影响[J].临床军医杂志, 2015, 43(11):1161. [8] 刘苔, 马荣炜, 杜卫祺, 等.大剂量氨溴索在AECOPD中的应用[J].临床肺科杂志, 2017, 22(5):890. doi: 10.3969/j.issn.1009-6663.2017.05.032 [9] 张明远.大剂量盐酸氨溴索在胸外科围手术期的肺功能保护[J].中国药物与临床, 2017, 17(8):1164. [10] 李金萍, 雷敏刚.盐酸氨溴索注射液对急性呼吸窘迫综合征新生儿血浆ET-1水平的影响[J].检验医学与临床, 2017, 14(17):2625. doi: 10.3969/j.issn.1672-9455.2017.17.051 [11] 付政平.氨溴索肺泡灌洗对支气管扩张合并感染患者肺功能及动脉血气指标的影响[J].中国临床医生杂志, 2017, 45(10):45. doi: 10.3969/j.issn.2095-8552.2017.10.017 [12] KANIE S, YOKOHIRA M, YAMAKAWA K, et al.Suppressive effects of the expectorant drug ambroxol hydrochloride on quartz-induced lung inflammation in F344 rats[J].J Toxicol Pathol, 2017, 30(2):153. [13] 王晓宏, 谷平, 唐军.大剂量氨溴索治疗老年重症肺炎的临床研究[J].临床肺科杂志, 2015, 20(10):1860. doi: 10.3969/j.issn.1009-6663.2015.10.036 [14] LEI Q, XU A, GOU C, et al.Dosimetric study of GZP660Co high dose rate brachytherapy source[J].J Appl Clin Med Phys, 2018, 19(4):313. doi: 10.1002/acm2.12362